CellGenix Appoints Leading Experts to Scientific Advisory Board

CellGenix, a global leader in providing GMP-grade raw materials for cell and gene therapy and tissue-engineered products, today announced the appointment of highly experienced and internationally respected experts in the field of cell and gene therapy to its Scientific Advisory Board (SAB). The SAB will serve as a strategic resource to CellGenix as it continues to develop high quality raw materials used worldwide in cell, gene therapy and regenerative medicine.

"We are delighted to have attracted these renowned experts to the SAB," says Prof. Dr. Felicia Rosenthal, CEO of CellGenix. "They join at an exciting time for CellGenix as the field is advancing rapidly and we are increasing our R&D investment. We are convinced that the background and experience of our SAB members will bring new ideas for our product development pipeline. Their input is especially welcome as we are working on various promising products for the future."

The members of CellGenix’ Scientific Advisory Board are:

• Cliona Rooney, Ph.D., is a Professor in the Center for Cell and Gene Therapy at Baylor College of Medicine. Prof. Rooney brings over 20 years of expertise in the field of T cell immunotherapy for virus-associated diseases and cancer. She was instrumental in the development of T-cell therapies virus-specific T-cells in the stem cell transplant setting and has further developed and refined antigen-specific T-cells for the treatment of cancer. Her current interests are in gene modifications and other strategies to render T-cells effective within an immunosuppressive microenvironment.
• Mitchell H. Finer, Ph.D., brings three decades of experience in the areas of regenerative medicine, cancer immunotherapy and cell and gene therapy, where he helped to advance products from conception through phase III clinical programs.  Dr. Finer founded Oncorus and currently serves as CEO and CSO. In 2015 he joined MPM Capital as Managing Director and is a member of the board of directors of MPM portfolio company Semma Therapeutics. Prior to MPM, Dr. Finer served as CSO of bluebird bio, where he was responsible for strategic elaboration of bluebird’s gene-modified adult hematopoietic stem cell therapy business and led the strategic development and partnering of CAR-T and genome engineering programs.
• Anthony Davies, Ph.D., is the founder and executive chairman of Dark Horse Consulting, a consultancy agency focused on CMC and product development issues in monoclonal antibody and cell and gene therapies. Dr. Davies brings along more than two decades of experience in the cell and gene therapy field. Over this period he has held positions of increasing responsibility at companies including Onyx Pharmaceuticals, Geron Corporation and Capricor.

About CellGenix
CellGenix is a leading manufacturer and developer of premium-grade reagents for clinical cell culture needs. The company has more than two decades of in-house expertise in GMP manufacturing and development of products in the field of cell therapy, gene therapy and regenerative medicine. The superior quality GMP reagents are used by leading experts and are proven in clinical trials and commercial manufacturing throughout the world. CellGenix is headquartered in Freiburg, Germany and operates a subsidiary in Portsmouth, New Hampshire, USA, serving the North American market.